Back

Effects of rivaroxaban on vascular endothelial function and circulating endothelial progenitor cells: a randomized controlled trial

1 September 2024 (14:00 - 14:50)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in coronary artery disease: from bench to bedside (2) Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Ms Min-Qing Lin

Hong Kong (Hong Kong)

6 More presentations in this session

Presentation thumbnail
Levosimendan improves the early prognosis of patients with Non ST-segment elevation myocardial infarction and Killip class > II
Doctor T. Gu (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Exploring the long-term effects of dapagliflozin in patients with stable acute myocardial infarction and preserved ejection fraction through a propensity score matching study
Doctor B. Hsiao (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Restrictive versus liberal blood transfusion strategies in patients with myocardial infarction and anemia: individual patient data meta-analysis of randomized trials
Professor J. Carson (New Brunswick, US)
Abstract Slides Video
Presentation thumbnail
CSWT improves ventricular function by promoting angiogenesis through Rho/ROCK/ERK1/2 signal pathway in infarcted myocardium in rats
Professor Y. Wang (Kunming, CN)
Abstract Slides Video
Presentation thumbnail
Drug-coated balloon for de-novo coronary artery lesions exceeding 2.5 mm in diameter: optical coherence tomography analysis and clinical follow-up
Doctor L. Guo (Dalian, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy in coronary artery disease: from bench to bedside (2)

The Event

Event poster

ESC Congress 2024

1 September 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
PCSK-9-inhibitor therapy improves endothelial function in patients with coronary artery disease
thumbnail
Congress Presentation
Safety and efficacy of prolonged antithrombotic therapy in high-risk patients followed in a dedicated secondary prevention consultation
thumbnail
Congress Session
HOT LINE 5

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources